216 related articles for article (PubMed ID: 32342707)
1. Companion and complementary diagnostics: an important treatment decision tool in precision medicine.
Jørgensen JT
Expert Rev Mol Diagn; 2020 Jun; 20(6):557-559. PubMed ID: 32342707
[No Abstract] [Full Text] [Related]
2. Implementing the EU in vitro diagnostic regulation - a European regulatory perspective on companion diagnostics.
Ritzhaupt A; Hayes I; Ehmann F
Expert Rev Mol Diagn; 2020 Jun; 20(6):565-567. PubMed ID: 31976775
[No Abstract] [Full Text] [Related]
3. An interview with Dr. Edward Abrahams on companion and complementary diagnostics in the era of personalized medicine.
Abrahams E
Expert Rev Mol Diagn; 2020 Jun; 20(6):561-563. PubMed ID: 32148107
[No Abstract] [Full Text] [Related]
4. Predictive biomarkers and clinical evidence.
Jørgensen JT
Basic Clin Pharmacol Toxicol; 2021 May; 128(5):642-648. PubMed ID: 33665955
[TBL] [Abstract][Full Text] [Related]
5. The evolving potential of companion diagnostics.
Khoury JD
Scand J Clin Lab Invest Suppl; 2016; 245():S22-5. PubMed ID: 27433788
[TBL] [Abstract][Full Text] [Related]
6. Update on molecular companion diagnostics - a future in personalized medicine beyond Sanger sequencing.
Campbell MR
Expert Rev Mol Diagn; 2020 Jun; 20(6):637-644. PubMed ID: 32167388
[TBL] [Abstract][Full Text] [Related]
7. Establishing the Evidence Bar for Molecular Diagnostics in Personalised Cancer Care.
Schneider D; Bianchini G; Horgan D; Michiels S; Witjes W; Hills R; Plun-Favreau J; Brand A; Lawler M;
Public Health Genomics; 2015; 18(6):349-58. PubMed ID: 26571110
[TBL] [Abstract][Full Text] [Related]
8. Challenges in the clinical implementation of precision medicine companion diagnostics.
Keeling P; Clark J; Finucane S
Expert Rev Mol Diagn; 2020 Jun; 20(6):593-599. PubMed ID: 32336167
[TBL] [Abstract][Full Text] [Related]
9. Regulatory perspectives on next-generation sequencing and complementary diagnostics in Japan.
Shimazawa R; Ikeda M
Expert Rev Mol Diagn; 2020 Jun; 20(6):601-610. PubMed ID: 32064968
[TBL] [Abstract][Full Text] [Related]
10. Cancer drug development and the evolving regulatory framework for companion diagnostics in the European union.
Pignatti F; Ehmann F; Hemmings R; Jonsson B; Nuebling M; Papaluca-Amati M; Posch M; Rasi G
Clin Cancer Res; 2014 Mar; 20(6):1458-68. PubMed ID: 24634469
[TBL] [Abstract][Full Text] [Related]
11. CDx, NGS and regulation: five perspectives from the Pistoia Alliance.
Wise J; Furness M; McWilliams S; Patton S
Drug Discov Today; 2019 Nov; 24(11):2120-2125. PubMed ID: 31306783
[TBL] [Abstract][Full Text] [Related]
12. Developing precision medicine in a global world.
Rubin EH; Allen JD; Nowak JA; Bates SE
Clin Cancer Res; 2014 Mar; 20(6):1419-27. PubMed ID: 24634465
[TBL] [Abstract][Full Text] [Related]
13. [Companion Diagnostics for Solid Tumors].
Watanabe A
Rinsho Byori; 2015 Nov; 63(11):1310-5. PubMed ID: 26995877
[TBL] [Abstract][Full Text] [Related]
14. Molecular tools for companion diagnostics.
Zieba A; Grannas K; Söderberg O; Gullberg M; Nilsson M; Landegren U
N Biotechnol; 2012 Sep; 29(6):634-40. PubMed ID: 22634023
[TBL] [Abstract][Full Text] [Related]
15. Preclinical Molecular Imaging for Precision Medicine in Breast Cancer Mouse Models.
Fiordelisi MF; Auletta L; Meomartino L; Basso L; Fatone G; Salvatore M; Mancini M; Greco A
Contrast Media Mol Imaging; 2019; 2019():8946729. PubMed ID: 31598114
[TBL] [Abstract][Full Text] [Related]
16. [Personalized drug therapy based on genetics. Possibilities and examples from clinical practice].
Stingl JC; Just KS; Kaumanns K; Schurig-Urbaniak M; Scholl C; von Mallek D; Brockmöller J
Internist (Berl); 2016 Mar; 57(3):289-97. PubMed ID: 26830424
[TBL] [Abstract][Full Text] [Related]
17. Companion and complementary diagnostics for infectious diseases.
Dailey PJ; Elbeik T; Holodniy M
Expert Rev Mol Diagn; 2020 Jun; 20(6):619-636. PubMed ID: 32031431
[TBL] [Abstract][Full Text] [Related]
18. Current Status of Companion and Complementary Diagnostics: Strategic Considerations for Development and Launch.
Scheerens H; Malong A; Bassett K; Boyd Z; Gupta V; Harris J; Mesick C; Simnett S; Stevens H; Gilbert H; Risser P; Kalamegham R; Jordan J; Engel J; Chen S; Essioux L; Williams JA
Clin Transl Sci; 2017 Mar; 10(2):84-92. PubMed ID: 28121072
[TBL] [Abstract][Full Text] [Related]
19. Innovative diagnostic technologies and their significance for personalized medicine.
Jain KK
Mol Diagn Ther; 2010 Jun; 14(3):141-7. PubMed ID: 20560675
[TBL] [Abstract][Full Text] [Related]
20. Lessons Learned When Introducing Pharmacogenomic Panel Testing into Clinical Practice.
Rosenman MB; Decker B; Levy KD; Holmes AM; Pratt VM; Eadon MT
Value Health; 2017 Jan; 20(1):54-59. PubMed ID: 28212969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
